Zhenchuan Song

河北医科大学

H指数:14

被引数:654

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Independent Risk Factors and a New Nomogram for Predicting Breast Cancer Risk for Bone Metastasis in Chinese Women: A Retrospective Study with External Validation

中国女性乳腺癌骨转移风险预测的独立危险因素及新型诺模图：一项含外部验证的回顾性研究

Journal of Clinical Medicine

IF2.9

2026-04-060

OAAI

Multidimensional cell-free DNA fragmentomics enables early detection of breast cancer

多维度的细胞外游离DNA片段组学能够实现乳腺癌的早期检测

Breast Cancer Research

IF5.6

2025-12-090

OAAI

ATP6V0D2 drives triple-negative breast cancer progression and inhibits cisplatin sensitivity by promoting PHLPP2 lysosomal degradation

ATP6V0D2通过促进PHLPP2的溶酶体降解，驱动三阴性乳腺癌的进展并抑制顺铂敏感性。

iScience

IF4.1

2025-10-270

OAAI

A retrospective study on axilla treatment for breast cancer with sentinel lymph node micrometastases

一项关于乳腺癌前哨淋巴结微转移患者腋窝治疗方案的回顾性研究

MEDICINE

IF1.4

2025-10-170

PRE

Eribulin plus Pyrotinib in Trastuzumab-Resistant; HER2-Positive Advanced Breast Cancer: A Single-Arm; Multicenter Phase II Trial (EPIC Trial)

Eribulin联合Pyrotinib治疗曲妥珠单抗耐药；HER2阳性晚期乳腺癌：一项单臂、多中心II期临床试验（EPIC试验）

drug design development and therapy

IF0

2025-09-180

The role of ATP6V0D2 in breast cancer: associations with prognosis, immune characteristics, and TNBC progression

ATP6V0D2在乳腺癌中的作用: 与预后，免疫特征和TNBC进展的关联

FRONTIERS IN ONCOLOGY

IF3.3

2024-11-291

OAAI

LncRNA DDX11-AS1 promotes breast cancer progression by targeting the miR-30c-5p/MTDH axis

LncRNA DDX11-AS1通过靶向miR-30c-5p/MTDH轴促进乳腺癌进展

SCIENTIFIC REPORTS

IF3.9

2024-11-050

OAAI

The prognostic analysis of further axillary dissection in breast cancer with 1-2 positive sentinel lymph nodes undergoing mastectomy

FRONTIERS IN ONCOLOGY

IF3.3

2024-08-051

OAAI

Risk factors and a new predictive nomogram for predicting the Non-sentinel Lymph Node Metastasis in 708 early-stage Breast Cancer Patients with Positive Sentinel Nodes in China

CANCER RESEARCH

IF16.6

2024-05-020

PRE

A new prediction nomogram of non-sentinel lymph node metastasis in cT1-2 breast cancer patients with positive sentinel lymph nodes

SCIENTIFIC REPORTS

IF3.9

2024-04-264

OAAI

Role of glutaminyl-peptide cyclotransferase in breast cancer doxorubicin sensitivity

CANCER BIOLOGY & THERAPY

IF4.6

2024-02-284

OAAI

Bioinformatic analysis reveals an association between Metadherin with breast cancer prognosis and tumor immune infiltration

SCIENTIFIC REPORTS

IF3.9

2024-01-231

OAAI

Metadherin inhibits chemosensitivity of triple-negative breast cancer to paclitaxel via activation of AKT/GSK-3β signaling pathway

CHEMICAL BIOLOGY & DRUG DESIGN

IF3.3

2023-12-131

PRE

Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial

Pyrotinib联合卡培他滨治疗曲妥珠单抗耐药的HER2-positive晚期乳腺癌 (图片): 一项单臂多中心2期试验

BMC MEDICINE

IF8.3

2023-08-0911

OAAI

Exploring risk factors for totally implantable venous access devices (TIVADs)-related thrombotic occlusion in the off-treatment period

SCIENTIFIC REPORTS

IF3.9

2023-07-044

OAAI

Monitoring circulating platelet activity to predict cancer-associated thrombosis

CELL REPORTS METHODS

IF4.5

2023-07-014

OAAI

Nanoparticle-Based Combination Therapy Enhances Fulvestrant Efficacy and Overcomes Tumor Resistance in ER-Positive Breast Cancer

CANCER RESEARCH

IF16.6

2023-06-166

PRE

PyrotInib in combination with Capecitabine for trasTUzumab-REsistant, HER2-positive advanced breast cancer (PICTURE): a multicenter phase 2 trial

CANCER RESEARCH

IF16.6

2023-03-010

PRE

Research on shifting process control of automatic transmission

SCIENTIFIC REPORTS

IF3.9

2022-07-294

OAAI

Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study

聚乙二醇化多柔比星脂质体、多西他赛和曲妥珠单抗作为HER2-Positive乳腺癌患者的新辅助治疗: II期和生物标志物研究

FRONTIERS IN ONCOLOGY

IF3.3

2022-07-088

OAAI

Zhenchuan Song

个人简介

教育背景

工作经历

荣誉奖项

研究方向